Dato-DXd

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
May, 2025
May 2025
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  

Dato-DXd
May 4, 2025, 03:18 | Insight
Raffaele Colombo highlights FDA Breakthrough Device Designation for Roche’s TROP2 diagnostic assay
Raffaele Colombo, Associate Director of Medicinal Chemistry at Zymeworks, shared a post on X by…
Apr 14, 2025, 18:08 | Science
Ming-Hei Tai: How should we interpret the new TROPION-Breast01 data
Ming-Hei Tai, Clinical Pharmacy Specialist at Karmanos Cancer Institute, shared a post on LinkedIn about…
Feb 25, 2025, 09:33 | Insight
Paolo Tarantino: Does Trop2 expression matter in the context of Dato-DXd treatment of mBC?
Paolo Tarantino, Advanced Research Fellow at Dana-Farber Cancer Institute, shared a post on X: "Does…
Jan 20, 2025, 13:55 | Blog
Paolo Tarantino: 10 facts to know on Dato-DXd
Paolo Tarantino, Advanced research fellow at Dana-Farber Cancer Institute, posted on LinkedIn: "Dato-DXd is the…
Nov 15, 2024, 15:14 | Blog
Brian Shields: AstraZeneca withdraws Lung Cancer Application for TROP2 - directed ADC
Brian Shields, Creator of KOL Pulse AI, shared a post on LinkedIn: "PR professionals in Pharma…
Oct 9, 2024, 11:40 | Insight
Datopotamab Deruxtecan Trial Shows Negative OS in TROPION-Lung 01 - Panot Sainamthip
"Recent data updates from the International Association for the Study of Lung Cancer 2024 World…
Sep 18, 2024, 16:29 | Blog
Francisco J. Esteva: A new era in personalized medicine for high-risk stage 2/3 breast cancer
Francisco J. Esteva, Chief, Division of Hematology and Medical Oncology at Lenox Hill Hospital, shared…
Sep 14, 2024, 06:35 | Opinion
Paolo Tarantino: Interesting data with TROP2 quantitative continuous scoring to predict Dato-DXd activity in lung cancer
Paolo Tarantino posted the following on X: “Interesting data with TROP2 quantitative continuous scoring (QCS)…
Sep 12, 2024, 09:48 | Insight
Datopotamab deruxtecan vs docetaxel for previously treated advanced NSCLC
Erman Akkus shared a post on X about a recent paper by Myung-Ju Ahn et…
Sep 11, 2024, 08:57 | Insight
TROPION-Lung01 Presents Further Data on Dato-DXd for NSCLC at WCLC - ASCO
American Society of Clinical Oncology (ASCO) shared a post on LinkedIn: "Lung Cancer Study (TROPION-Lung01)…
May 16, 2024, 16:51 | Insight
10 Most Promising Cancer Drugs Not Yet Approved: Solid Tumors - 2024 edition by OncoDaily
In the fast-growing field of oncology, we are witnessing significant advances in several treatment modalities…
Feb 22, 2024, 18:56 | Blog
Raffaele Colombo: Application based on results from the TROPION-Lung01 phase 3 trial
Raffaele Colombo, Principal Scientist & Group Lead, Medicinal Chemistry at Zymeworks, shared on X/Twitter: "Application based…
Dec 30, 2023, 17:51 | Opinion
Paolo Tarantino: Happy to have worked with Sarah Sammons and Nancy Lin at the ph2 DATO-Base trial
Paolo Tarantino, Medical Oncologist and Research Fellow at the Dana-Farber Cancer Institute, shared a post…
All: 13 Posts: 1 - 100
Special Coverage